91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Worldwide demand for cancer therapies is set to soar – and biomanufacturers are in the spotlight. Explore emerging industry data to distinguish trends and prepare for the future of oncology.
-
Targeted product profiles and biomarkers for patient screening are essential elements of success for oncology treatment developers, according to our recent survey. This article explores why both prove challenging for drug developers.
-
This article explores the imperatives and strategies for commercialising oncology treatments targeting young adults, highlighting the need for innovative regulatory and commercial strategies to ensure successful market entry and improved patient outcomes.
-
This article published in The Pharma Letter highlights findings from an 91黑料 survey has found that despite the increasing investment in emerging oncology-related therapeutics, developers have varied views on the impact of new cancer drugs for patients.
-
Read insights from Harpreet Gill VP, Real World Solutions, on how sponsors can optimise their LTFU studies to be flexible and cost-effective, with strategic planning and innovation, overcoming challenges while capturing valuable data insights.
-
This news piece from Precision Medicine Online provides an overview of the findings from 91黑料’s recent survey of professionals engaged in oncology-related clinical research. It shares respondents' insights on how precision medicine approaches are changing development strategies and the to the extent these therapeutic advances will benefit patients in the future.
-
In this media article, 91黑料 expert Tanja Obradovic, PhD, highlights how mapping clear inflection points for data-driven decisions will inform efficient drug development.
-
In this article, 91黑料’s Andreas Dreps reviews the innovations that have helped ADCs overcome clinical development challenges.
-
In this article, 91黑料's Brian Huber explains why and discusses the prospects for the next-generation of CAR T-cell therapies engineered to be more adaptable, precise and controlled.
-
.jpg?w=545&itok=Tgn4zMcc "EPR in healthcare news.")
This Q&A with Dr Jin Li and Dr Chad Galderisi of 91黑料 Specialty Laboratory Solutions discusses 91黑料’s development of its RNA-based next generation sequencing (NGS) assay that detects mutations in chronic myeloid leukemia (CML) and how it can benefit both routine clinics and clinical trial settings.
.jpg?w=340&itok=AZLofY9I "EPR in healthcare news."){kind=icon}